Abstract Purpose: The pathogenic CHEK2 1100delC variant is firmly established as a breast cancer susceptibility allele. Dutch CHEK2 1100delC breast cancer families frequently also include colorectal cancer cases, and the variant is particularly prevalent among breast cancer families with hereditary breast and colorectal cancer. Yet, it is still unclear whether CHEK2 1100delC also confers a colorectal cancer risk independent of its breast cancer risk. Experimental Design: CHEK2 1100delC was genotyped in the index cases of 369 Dutch colorectal cancer families that had been excluded for familial breast cancer. The cohort included 132 cases with familial adenomatous polyposis (FAP) and FAP-related disease, and 237 cases with hereditary nonpolyposis colorectal cancer (HNPCC) and HNPCC-related disease. Results: None of the FAP/FAP-related cases carried the CHEK2 1100delC variant. In contrast, CHEK2 1100delC was present in 10 of 237 (4.2%) HNPCC/HNPCC-related cases that was significantly more prevalent than the 1.0% Dutch population frequency (odds ratio, 4.3; 95% confidence interval, 1.7-10.7; P = 0.002). Nine of the10 CHEK2 1100delC colorectal cancer cases met the revised Amsterdam and/or Bethesda criteria. The 10 CHEK2 1100delC colorectal cancer families had a high-risk cancer inheritance pattern, including 35 colorectal cancer cases, 9 cases with polyps, and 21cases with other tumor types. Conclusion: Our analysis provides strong evidence that the1100delC variant of CHEK2 confers a colorectal cancer risk in HNPCC/HNPCC-related families, supporting the hypothesis that CHEK2 is a multiorgan cancer susceptibility gene.
In 2002, we and others identified CHEK2 1100delC (MIM 604373) as a breast cancer susceptibility allele (1 -4) . The CHEK2 1100delC variant was present in 5% of non-BRCA1/ BRCA2 breast cancer families compared with only 1% in the general population. Although variants with a population frequency of 1% or more are often considered polymorphisms, the estimated 2-fold increased breast cancer risk for female CHEK2 1100delC carriers had classified CHEK2 1100delC as a pathogenic moderate-risk mutation. Strikingly, the prevalence of CHEK2 1100delC increased with increasing numbers of breast cancer cases in the families, suggesting a rather high-risk breast cancer inheritance pattern for the variant. Also, the CHEK2 1100delC genotype only partially segregated with the breast cancer phenotype, particularly so in families that were more severely affected with breast cancer. Together, these apparent discrepancies have suggested a polygenic breast cancer susceptibility model for the CHEK2 1100delC variant, in which CHEK2 1100delC acts in concert with another as-yet-unknown breast cancer susceptibility allele or alleles (1 -5) .
We had noted that near half of Dutch CHEK2 1100delC breast cancer families also included colorectal cancer cases (11 of 25 families, together with 21 cases; refs. 1, 6) . Indeed, when we applied stringent clinical criteria to define a new subtype of breast cancer families with a ''hereditary breast and colorectal cancer'' (HBCC) phenotype, the CHEK2 1100delC frequency was almost five times higher among the HBCC families compared with breast cancer families not fulfilling the HBCC criteria (18% versus 4%; ref. 6 ). These results thus suggested that CHEK2 1100delC carriers may also be predisposed to develop colorectal cancer. To evaluate the colorectal cancer risk conferred by CHEK2 1100delC independent of its breast cancer risk, we here have genotyped CHEK2 1100delC in 369 Dutch familial colorectal cancer cases.
Materials and Methods
Colorectal cancer families. The selected familial colorectal cancer cohort (n = 385) included all colorectal cancer families registered by the Dutch Foundation for Detection of Hereditary Tumors and those that were registered by the Rotterdam Family Cancer Clinic at Erasmus Medical Center. Sixteen hereditary nonpolyposis colorectal cancer (HNPCC)-related families had been excluded because they met our criteria for familial breast cancer [i.e., at least two first-or second-degree relatives (DGR) with breast cancer of whom at least one was diagnosed before age 60 y]. The evaluated Dutch Foundation for Detection of Hereditary Tumors cohort (cohort I) included 114 HNPCC/HNPCCrelated and 91 familial adenomatous polyposis (FAP)/FAP-related families that had been reported as part of another CHEK2 1100delC study (6) . The evaluated Erasmus Medical Center cohort (cohort II) included 123 HNPCC/HNPCC-related and 41 FAP/FAP-related families. All cases have consented to search for cancer susceptibility genes and the Medical Ethical Review Board at Erasmus Medical Center has approved the study.
Population controls. The 909 population-matched controls all originated from the southwestern Netherlands and included a hospital-based cohort of 184 spouses of heterozygous cystic fibrosis mutation carriers ascertained through the department of Clinical Genetics at Erasmus Medical Center, a population-based cohort of 460 persons without cancer after age 55 y from the Erasmus Rotterdam Health and the Elderly Study and a cohort of 265 randomly selected blood donors (5) .
Mutation screening of colorectal cancer families. The complete coding sequences of the APC, MUTYH, MLH1, MSH2, and MSH6 genes were analyzed for mutations, including all known Dutch founder mutations, deletions, and rearrangements, in a routine clinical genetics diagnostic setting, as described (6, 7) . For each family, mutation screening was done in blood-derived DNA of at least the colorectal cancer case with the youngest age at diagnosis for whom DNA was available (index case). CHEK2 1100delC screening was done on bloodderived DNA of the index case by allele-specific oligonucleotide hybridization. This method includes PCR amplification of CHEK2 (ENSG00000183765) exon 10, application of the amplified products to nylon filters, and hybridization under high stringency to [ 32 P] oligonucleotides that are complementary to the CHEK2 1100delC or CHEK2 wild-type sequence. Amplification of exons 9 through 14 by long-range PCR and subsequent sequencing of a nested PCR product using primers flanking exon 10 confirmed all positive CHEK2 1100delC cases. CHEK2 1100delC screening methods are described in detail in reference (1) .
Statistical analysis. The difference between CHEK2 1100delC carriers in colorectal cancer cases and controls was analyzed using Fisher's Exact Test. Odds ratios and 95% confidence intervals were calculated from two-by-two tables. All analyses were done with SPSS version 11.
Results and Discussion
Characterization of colorectal cancer families. The 369 colorectal cancer families screened for CHEK2 1100delC were 120435) and HPNCC-related families. Of the 132 FAP/FAP-related families, 86 (65%) had a pathogenic germline mutation in APC (MIM 175100), 10 (8%) had a pathogenic germline mutation in MUTYH (MIM 604933), and another 36 (27%) families included cases that had been diagnosed with >20 adenomatous polyps. The 237 HNPCC/ HNPCC-related families were classified according to the presence of a pathogenic germline mismatch repair (MMR) gene mutation or otherwise by distribution and mode of inheritance of colorectal cancer cases in the family. The 83 MMR mutation -positive families included 38 (46%) MLH1 (MIM 120436), 34 (41%) MSH2 (MIM 120435), and 11 (13%) MSH6 (MIM 600678) mutation -positive HNPCC families. Analysis of microsatellite instability (MSI) was done in approximately one-third of these families showing that 22 (81%) index cases had an MSI-high, 4 (15%) had an MSI-low, and 1 (4%) had an MSI-stable phenotype. Extensive mutational screening of MLH1, MSH2, and MSH6 had failed to identify pathogenic mutations, deletions, or rearrangements in 154 HNPCC/HNPCC-related families. These 154 MMR mutationnegative families were classified by either the presence of at least two first DGRs with colorectal cancer of whom at least one was diagnosed before age 50 y (n = 95; 62%) or by the presence of at least two first DGRs with colorectal cancer but none of them diagnosed before age 50 y (n = 36; 23%) or by the presence of a single colorectal cancer case diagnosed before age 50 y (n = 23; 15%). MSI data were available for 100 (65%) MMR mutation -negative HNPCC/HNPCC-related families. The majority of index cases (74%) among these families had an MSI-stable phenotype. MSI-high and MSI-low phenotypes were reported for 18% and 8% HNPCC/HNPCC-related families, respectively. Fifty-eight (38%) of the MMR mutation -negative families were classic HNPCC families as they fulfilled the revised Amsterdam criteria, and another 73 (47%) families had index cases that met the revised Bethesda criteria for MSI screening (8, 9) . The cancer incidences among the MMR mutation -negative HNPCC/HNPCC-related families are detailed in Table 1 , showing that the majority of families had at least three colorectal cancer cases and, thus, can be assigned as high-risk colorectal cancer families.
CHEK2 1100delC confers HNPCC/HNPCC-related colorectal cancer. Genetic screening for CHEK2 1100delC revealed that none of 132 FAP/FAP-related cases carried the variant (Table 2) . In contrast, 10 of 237 (4.2%) HNPCC/HNPCC-related cases carried CHEK2 1100delC compared with only 9 of 909 (1.0%) of population controls, implying a strong association of the variant with familial colorectal cancer (P = 0.002; Table 2 ). Our results thus indicate that CHEK2 1100delC confers a colorectal cancer risk. Moreover, we show that this risk is associated with HNPCC/HNPCC-related colorectal cancer rather than FAP/ FAP-related colorectal cancer.
Progressive insight in CHEK2 cancer susceptibility has revealed that various CHEK2 gene variants confer only low to moderate cancer risks and that the prevalences of these variants are highly variable among populations. These characteristics severely hamper evaluation of CHEK2 cancer risks. In an initial screen for CHEK2 1100delC in familial colorectal cancer cases, for example, we had found some suggestion of an HNPCC/ HNPCC-related colorectal cancer risk for the variant (6). However, the familial colorectal cancer cases in this screen had been collected through the International Concerted Action Polyp Prevention and the Dutch Foundation for Detection of Hereditary Tumors, including 114 Dutch cases, 50 German cases, 37 American cases, and several smaller cohorts from other countries. In retrospect, this case cohort was not only too divers regarding its geographic origins but also had not appropriately been stratified for population controls. The case cohort had included six CHEK2 1100delC mutant colorectal cancer cases, of which four originated from the Netherlands (15) 3/300 (1.0) USA-PA (14) 1/153 (0.7) UK-SE (18) 21/4,037 (0.5) c NOTE: The summary includes data from the present study and 10 studies that have thus far been published on CHEK2 1100delC in colorectal cancer cases (10 -19) . Colorectal cancer families from southwestern Netherlands were excluded for families that fulfilled our familial breast cancer criteria. The Finnish data set included nine cases with a personal or family history of breast cancer (with one CHEK2 1100delC case and the other two from Germany. When now properly compared with the Dutch population frequency of 1.0%, the 3.5% frequency of CHEK2 1100delC among the 114 Dutch HNPCC/HNPCC-related cases was significantly increased (P = 0.05; cohort I in Table 2 ). In the current study, we sought to further substantiate these initial findings and collected all available familial colorectal cancer cases from the Rotterdam Family Cancer Clinic at Erasmus Medical Center. Indeed, CHEK2 1100delC was again identified in HNPCC/HNPCCrelated cases but not in FAP/FAP-related cases, with 6 CHEK2 1100delC cases among 123 HNPCC/HNPCC-related cases (4.9% and P = 0.005; cohort II in Table 2 ). Clearly, reliable evaluation of CHEK2 cancer risks requires sufficiently large and homogeneous case cohorts that are appropriately matched for population controls. Upon combining both Dutch colorectal cancer case cohorts, we were now able to provide strong evidence that CHEK2 1100delC confers a colorectal cancer risk (4.1% and P = 0.002; Table 2 ). To date, the colorectal cancer risk of CHEK2 1100delC has been evaluated in 908 familial colorectal cancer cases and in 2,740 unselected colorectal cancer cases, derived from 10 independent studies (reviewed in Table 3 ; refs. 10 -19). As a whole, there was some suggestion that CHEK2 1100delC may confer a colorectal cancer risk. Yet, none of the reported studies had sufficient statistical power to show, beyond doubt, that CHEK2 1100delC is associated with colorectal cancer. Unfortunately, the inclusion criteria for the colorectal cancer cases differed substantially among the reported studies and CHEK2 1100delC population frequencies were also highly variable, inducing us to refrain from meta-analysis of the combined results. Our current study therefore is the very first to establish an HNPCC/HNPCC-related colorectal cancer risk for the CHEK2 1100delC variant. One other CHEK2 variant (I157T) has also been associated with colorectal cancer, in both the Finnish and the Polish populations (10, 11, 20) . The colorectal cancer risk of CHEK2 is thus not limited to the 1100delC variant. Similar to what has recently been done for other breast cancer genes (21 -25) , the full spectrum of CHEK2 -associated cancer risks should therefore be established by whole CHEK2 gene screens, in large sample cohorts that preferably also include cancer cases of other tumor types.
CHEK2 1100delC and polygenic cancer susceptibility. The 10 CHEK2 1100delC colorectal cancer families that we here have identified included 8 MMR mutation -negative HNPCC/ HNPCC-related families and 2 families with a MMR mutation (MLH1 and MSH6; both reported earlier in ref. 6 ). Four CHEK2 1100delC families fulfilled the revised Amsterdam criteria for HNPCC disease, and five other families had index cases that met the revised Bethesda criteria. Together, the 10 CHEK2 1100delC colorectal cancer families included 35 colorectal cancer cases, 9 cases with polyps, and 21 cases with other tumor types (detailed in Table 4 ), implying that the CHEK2 1100delC families can be classified as high-risk colorectal cancer families.
We also genotyped CHEK2 1100delC in all nonindex cases from the CHEK2 1100delC families of whom DNA was available, including four cases with colorectal cancer, five cases with polyps, and four cases with other cancers in first, second, or third DGRs from the main cancer-prone branch of the families (Table 4) . One of four colorectal cancer cases carried CHEK2 1100delC, three of five cases with polyps were CHEK2 1100delC positive, and also one of four other cancers carried CHEK2 1100delC. As expected, cosegregation was better among first DGRs, with three CHEK2 1100delC -positive cases who had polyps and one case who was diagnosed with ovarian cancer among six affected first DGRs (no DNA was available of first DGRs with colorectal cancer). Altogether, our analysis thus shows incomplete cosegregation of the CHEK2 1100delC genotype with the cancer phenotype in these families, suggesting the presence of an additional cancer susceptibility allele or alleles.
Although our current study design does not allow for an accurate estimate of the colorectal cancer risk conferred by CHEK2 1100delC, the observed 4.3 odds ratio does not account for the high-risk colorectal cancer inheritance pattern observed in the CHEK2 1100delC families. The high-risk inheritance pattern together with the incomplete cosegregation of the CHEK2 1100delC variant suggests a polygenic colorectal cancer susceptibility model, similar to the current ideas on CHEK2 -related breast cancer susceptibility (1 -5) . Consistent with a polygenic model, three of the CHEK2 1100delC colorectal cancer families had not inherited CHEK2 1100delC through the main cancer-prone family branch (Table 4) . Further support for a polygenic CHEK2 model involves the dramatic and unprecedented high CHEK2 1100delC prevalence among Dutch families with HBCC compared with families with only breast cancer or colorectal cancer (18% versus each 4%; refs. 1, 6). It seems that at least two cancer susceptibility alleles in addition to CHEK2 1100delC are inherited in these HBCC families. One thus might wonder whether CHEK2 is a breast cancer gene, a colorectal cancer gene, or a multiorgan gene-as was rightly suggested before (10, 20) . Or, alternatively, is it the additional cancer susceptibility alleles that determine organ specificity? In the HBCC families, one of these would then determine the breast cancer phenotype, whereas the other determines the colorectal cancer phenotype. In this scenario, CHEK2 1100delC would be a modifier that only increases cancer risks for carriers of the other susceptibility alleles. Comprehension of the exact nature of polygenic CHEK2 cancer susceptibility clearly awaits identification of the additional cancer susceptibility alleles. Our finding that CHEK2 1100delC specifically associates with HNPCC-related colorectal cancer suggests that the MMR genes might also be involved in breast cancer families with the HBCC phenotype.
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